University of British Columbia Vancouver, British Columbia, Canada.
Ther Clin Risk Manag. 2007 Mar;3(1):59-69. doi: 10.2147/tcrm.2007.3.1.59.
Panic disorder is a chronic, recurrent illness, with a lifetime prevalence of about 5%. It is associated with substantial functional impairment, and studies suggest that treatment with medication alone (and no instruction in exposure to feared and avoided situations) is less than optimal. In fact, 40%-90% of patients in long-term follow-up studies in the late 1980s and early 1990s, treated with antidepressants or high potency benzodiazepines alone, remained somewhat symptomatic. Venlafaxine extended release (XR) was effective and well tolerated in both the short-term and long-term treatment of panic disorder. In 12-week trials, venlafaxine XR was significantly more effective than placebo in achieving a panic-free state (54%-70% vs 34%-48%, p</=0.05), and was as effective as paroxetine. In addition, venlafaxine XR has been shown to produce significantly higher response and remission rates than placebo. Relapse rates were significantly reduced with ongoing venlafaxine XR treatment compared to switching to placebo (22% vs 50%, p</=0.001), in a 6 month study. Importantly, venlafaxine XR significantly improved patient quality of life and functioning, and was generally well tolerated.
惊恐障碍是一种慢性、复发性疾病，终身患病率约为 5%。它与严重的功能障碍有关，研究表明，仅用药物治疗（而不指导患者接触恐惧和回避的情况）效果不理想。事实上，在 20 世纪 80 年代末和 90 年代初的长期随访研究中，40%-90%的接受抗抑郁药或高活性苯二氮䓬类药物单独治疗的患者仍有一定的症状。文拉法辛缓释剂（XR）在惊恐障碍的短期和长期治疗中均有效且耐受性良好。在 12 周的试验中，文拉法辛 XR 在达到无惊恐状态方面明显优于安慰剂（54%-70%比 34%-48%，p</=0.05），与帕罗西汀相当。此外，文拉法辛 XR 显示出比安慰剂更高的反应和缓解率。与转换为安慰剂相比，持续文拉法辛 XR 治疗可显著降低复发率（22%比 50%，p</=0.001），这是一项为期 6 个月的研究。重要的是，文拉法辛 XR 显著改善了患者的生活质量和功能，且总体上耐受性良好。
